Equities research analysts expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to announce sales of $5.58 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for G1 Therapeutics’ earnings. The highest sales estimate is $6.71 million and the lowest is $5.20 million. G1 Therapeutics posted sales of $16.55 million in the same quarter last year, which suggests a negative year-over-year growth rate of 66.3%. The firm is scheduled to announce its next earnings results on Wednesday, February 23rd.
According to Zacks, analysts expect that G1 Therapeutics will report full year sales of $31.26 million for the current fiscal year, with estimates ranging from $30.90 million to $32.39 million. For the next financial year, analysts forecast that the firm will post sales of $46.58 million, with estimates ranging from $38.64 million to $58.92 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, November 3rd. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.03. G1 Therapeutics had a negative net margin of 316.58% and a negative return on equity of 65.66%. During the same period in the previous year, the firm posted ($0.31) earnings per share.
A number of institutional investors and hedge funds have recently made changes to their positions in GTHX. Fisher Asset Management LLC bought a new position in G1 Therapeutics in the second quarter valued at approximately $20,072,000. Nordea Investment Management AB lifted its stake in G1 Therapeutics by 319.0% in the third quarter. Nordea Investment Management AB now owns 793,244 shares of the company’s stock valued at $10,892,000 after buying an additional 603,929 shares in the last quarter. Morgan Stanley lifted its stake in G1 Therapeutics by 142.0% in the second quarter. Morgan Stanley now owns 572,061 shares of the company’s stock valued at $12,551,000 after buying an additional 335,635 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in G1 Therapeutics by 42.4% in the first quarter. Dimensional Fund Advisors LP now owns 845,067 shares of the company’s stock valued at $20,373,000 after buying an additional 251,613 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in G1 Therapeutics by 166.7% in the second quarter. Point72 Asset Management L.P. now owns 399,844 shares of the company’s stock valued at $8,773,000 after buying an additional 249,908 shares in the last quarter. 64.04% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:GTHX remained flat at $$13.66 during trading on Thursday. 470,240 shares of the stock traded hands, compared to its average volume of 1,155,083. G1 Therapeutics has a 12 month low of $11.98 and a 12 month high of $37.07. The company’s fifty day moving average is $14.07 and its 200-day moving average is $17.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.63 and a current ratio of 8.68. The company has a market capitalization of $580.85 million, a price-to-earnings ratio of -4.19 and a beta of 2.16.
About G1 Therapeutics
G1 Therapeutics, Inc engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Further Reading: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.